EUCTR2007-001078-94-NL进行中（未招募）1 期
Treatment of dumping syndrome with Lanreotide Autogel
Radboud University medical centre0 个研究点目标入组 12 人开始时间: 2007年4月6日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Selection on basis of the clinical diagnostic index devised by Sigstad.
- •- In addition their dumoing score after an oral glucose challenge is positive.
- •- patients with late dumping are selected on the basis of a history suggestive of postprandial hypoglycaemia, a plasme glucose of less than 3,0 mm/l at least 60 min after ingestion of 50 g glucose/m2 body surface and hypoglycaemic symptoms at least 60 min afetr oral glucise load.
- •- Most patients will be on lng term octreotide LAR therapy
- •- written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years)
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years)
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Patients with disorders of the endocrine system
- •- Patients with severe kidney,liver or cardiovascula disease.
- •- pregnant patients
- •- patients giving breast feeding
- •- patients with recent gastrointestinal surgery or other gastro-intestinal diseases
研究者
相似试验
尚未招募
4 期
Treatment of dumping syndrome with Lanreotide AutogelDumping syndrome10018012NL-OMON31107niversitair Medisch Centrum Sint Radboud12
尚未招募
不适用
Diagnosis and Treatment of Dumping Syndrome Using Ambulatory Blood Glucose Level Monitoring in Gastrectomized patientsKCT0005674The Catholic University of Korea, Seoul St. Mary's Hospital20
Unknown
4 期
Treatment of the Dumping Syndrome With Lanreotide Autogel®Dumping SyndromeNCT00543179Radboud University Medical Center
进行中（未招募）
1 期
Sandostatine LAR in Dumping syndrome - Dumping SyndromeDumping Syndrome is a condition characterized by weakness, dizziness, flushing and warmth, nausea and palpitation immediately or shortly after eating and produced by abnormally rapid emptying of the stomach in persons who have had part of the stomach removed or in hypersensitive or neurotic individualsEUCTR2005-003250-98-BEZ LEUVE
进行中（未招募）
不适用
Role of Lanreotide in the Management of Paraduodenal Pancreatitis - LPPParaduodenal pancreatitisMedDRA version: 12.1Level: LLTClassification code 10009093Term: Chronic pancreatitisEUCTR2009-016082-29-BEErasme hospital60